

# Contents

<b>WHO Expert Committee on Drug Dependence</b>	<b>v</b>
<b>General terms</b>	<b>vii</b>
<b>Chemical names</b>	<b>viii</b>
<b>Introduction</b>	<b>1</b>
<b>Declarations of interest</b>	<b>3</b>
<b>1. Briefings from international organizations on their work on the public health element of the world drug problem</b>	<b>4</b>
1.1 Update from the International Narcotics Control Board	4
1.2 Update from the United Nations Office on Drugs and Crime	5
1.3 Update from the Department of Essential Medicines and Health Products (WHO)	6
1.4 Update from the Department of Mental Health and Substance Abuse (WHO)	8
1.5 Update from the Department of HIV/AIDS	9
<b>2. Update from the second Informal Working Group of the ECDD</b>	<b>10</b>
<b>3. Follow-up on recommendations made by the ECDD at its thirty-eighth meeting</b>	<b>12</b>
3.1 U-47700	12
3.2 Butyrfentanyl	12
3.3 4-MEC	12
3.4 Ethylone	12
3.5 Pentedrone	13
3.6 Ethylphenidate	13
3.7 Methiopropamine (MPA)	13
3.8 MDMB-CHMICA	13
3.9 5F-APINACA	13
3.10XLR-11	13
<b>4. Proposed WHO surveillance system for new psychoactive substances (NPS)</b>	<b>14</b>
<b>5. Review of psychoactive substances</b>	<b>15</b>
5.1 AB-CHMINACA	15
5.2 5F-ADB/5F-MDMB-PINACA	17
5.3 4-Fluoroamphetamine (4-FA)	19
5.4 AB-PINACA	21
5.5 Ocfentanil	23
5.6 Furanyl fentanyl	24
5.7 Acryloylfentanyl (Acrylfentanyl)	26
5.8 Carfentanil	27

5.9	4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)	30
5.10	Tetrahydrofuranlyl fentanyl (THF-F)	32
5.11	UR-144	33
5.12	5F-PB-22	35
5.13	Etizolam (INN)	37
5.14	Pregabalin	39
5.15	Cannabidiol (CBD)	41
5.16	Tramadol	43
<b>6.</b>	<b>Cannabis pre-reviews: update on progress of planned reviews for 2018</b>	<b>46</b>
<b>7.</b>	<b>Other priorities for the ECDD</b>	<b>47</b>
7.1	Exemptions related to opioids in Schedule 3 of the 1961 Convention	47
7.2	Global opioid crisis: role of the ECDD	47
7.3	Future agenda items	47
	<b>Acknowledgements</b>	<b>48</b>
	<b>References</b>	<b>48</b>